Targeting the Source: Sagimet's Novel Drug Aims to Revolutionize Acne Treatment

SAN MATEO, CA – May 11, 2026 – Sagimet Biosciences is poised to take a significant step forward in the battle against acne, a condition affecting nearly 50 million Americans annually. The company announced today that it will present promising preclinical data for a new class of acne medication at the upcoming 83rd Society for Investigative Dermatology (SID) Annual Meeting. This move paves the way for a planned U.S. Phase 3 clinical trial for its lead drug, denifanstat, set to begin in the second half of 2026.

The announcement signals a potential paradigm shift in dermatology, moving beyond existing treatments to target the fundamental biological process that fuels acne: the overproduction of sebum, the skin’s natural oil. For the approximately 10 million people in the U.S. suffering from moderate to severe acne, a new, targeted oral therapy could represent a long-awaited breakthrough.

A Novel Mechanism to Target Acne at its Source

At the heart of Sagimet's approach is a novel mechanism of action that has garnered excitement among dermatological experts: the inhibition of Fatty Acid Synthase (FASN). FASN is a critical enzyme in a process called de novo lipogenesis (DNL), which is responsible for synthesizing the vast majority of lipids that make up sebum. In individuals prone to acne, this process goes into overdrive, leading to oily skin, clogged pores, inflammation, and the characteristic lesions of the condition.

"Excess sebum production is one of the key drivers of acne," stated Dr. Andreas Grauer, Sagimet's Chief Medical Officer, in the company's press release. The data to be presented at SID 2026 will show that FASN inhibitors, like denifanstat, can directly reduce these sebum-related lipids in human sebocytes, the skin cells that produce sebum.

Unlike many existing treatments that address the symptoms of acne—such as bacterial growth or inflammation—FASN inhibitors aim to cut off the problem at its source. One leading dermatologist, speaking on the condition of anonymity, described the mechanism as akin to "removing the fuel from the car so it cannot run." By directly suppressing the production of sebum, denifanstat has the potential to address both the oily complexion and the inflammatory cascades that follow.

This dual action is a key differentiator. Another expert, a clinical associate professor of dermatology, noted that "excess sebum production and inflammation are both foundational aspects of acne pathophysiology." She expressed optimism, stating, "We look forward to having this new agent in our acne toolbox." This targeted approach could offer a more sustained and effective solution, potentially reducing the need for chronic, multi-drug regimens.

From Chinese Trials to a U.S. Ambition

Sagimet's confidence in bringing denifanstat to a U.S. Phase 3 trial is not based on preclinical data alone. The drug, known as ASC40 in China, has already demonstrated significant success in a robust clinical development program conducted by Sagimet's partner, Ascletis Pharma Inc.

A Phase 2 study involving 180 patients with moderate to severe acne showed that ASC40 led to statistically significant reductions in both total and inflammatory acne lesions compared to a placebo. The drug was found to be safe and well-tolerated, with the most common side effect being mild dry eyes, an incidence similar to that seen in the placebo group.

More compellingly, topline results from a subsequent Phase 3 trial in China, presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, confirmed these findings on a larger scale. The trial showed that a 50 mg daily dose of the drug resulted in a remarkable 60% reduction in total lesions over 12 weeks. Crucially, the safety profile remained favorable, with no serious drug-related adverse events reported and a side effect profile comparable to the placebo group.

This successful track record in China provides a strong foundation for Sagimet's U.S. ambitions. By leveraging existing clinical data, the company can streamline its path toward a potential U.S. regulatory submission, bringing a promising new therapy to one of the world's largest pharmaceutical markets.

Reshaping the Crowded Acne Treatment Landscape

The current market for moderate to severe acne is filled with options, yet significant unmet needs persist. Patients often cycle through topical retinoids, benzoyl peroxide, and oral antibiotics, the latter of which raises concerns about long-term use and the development of antibiotic resistance.

For the most severe cases, the go-to treatment is often oral isotretinoin. While highly effective, it is associated with a range of severe side effects, including a high risk of birth defects, requiring strict monitoring and patient registration programs. For female patients, hormonal therapies like oral contraceptives or spironolactone are often used, but these are not suitable for all patients.

Denifanstat could carve out a crucial space within this landscape. As a non-hormonal, non-antibiotic oral medication with a novel mechanism and a favorable safety profile demonstrated in trials to date, it could become a first-line systemic therapy for patients who are not candidates for, or are unwilling to take, isotretinoin. One expert, a former vice president of the American Academy of Dermatology, anonymously called the drug a "potential game-changer" and a truly "novel molecule or mechanism" for the field.

If the U.S. Phase 3 trial replicates the success seen in China, denifanstat could offer dermatologists and their patients a powerful new tool for managing a chronic and often frustrating condition without the significant safety burdens of current high-efficacy treatments.

A Clearer Future for Acne Sufferers

Beyond the scientific and commercial implications, the potential arrival of a new, effective acne therapy carries profound significance for patients. Moderate to severe acne is not merely a cosmetic issue; it is a medical condition that can lead to permanent scarring and significant psychological distress, including anxiety, depression, and social isolation. The quest for a clear complexion often involves years of trial and error with treatments that can be irritating, inconvenient, or carry worrisome risks.

Sagimet's focus extends beyond dermatology, lending the company significant credibility. Denifanstat has also been granted Breakthrough Therapy designation by the FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease, highlighting the drug's potential across multiple metabolic pathways and the company's experience in navigating advanced regulatory channels.

As Sagimet prepares for its presentation at the SID 2026 meeting and looks ahead to its pivotal U.S. trial, the dermatology community and millions of acne sufferers will be watching closely. The journey of denifanstat from a novel concept to a potential new standard of care represents a beacon of hope for a clearer, more confident future for those living with acne.